Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial

BACKGROUND: In patients with relapsing-remitting MS (RRMS) fingolimod prevents disease relapses and delays disability progression. First dose administration of fingolimod is associated with a transient, dose-dependent decrease in heart rate (HR) in the 6 hours after drug intake.The aim of the study is to to assess safety and tolerability of the first dose of fingolimod in a cohort of Italian patients with RRMS without alternative therapeutic options. METHODS: Open-label, single arm, multicentre study. After the first dose of fingolimod, patients were observed for 6 hours and had their vital signs monitored hourly. Extended on-site monitoring was provided when required. RESULTS: Of the 906 p…

Grey matter and white matter atrophy in a large population of patients with multiple sclerosis: a 2 years follow-up study based on a fully automated MR segmentation method.

The Mini Mental State Examination (MMSE) for Cognitive Impairment in multiple sclerosis (ms): a two years Longitudinal study in 300 patients.

Correction to: Disability assessment using Google Maps (Neurological Sciences, (2022), 43, 2, (1007-1014), 10.1007/s10072-021-05389-7)

Originally, the article has been published online with a spelling error in author name. The correct author name is Paolo Ragonese and not Paolo Raganose. The original article has been corrected.